Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor 60 mg versus 90 mg twice daily in elderly patients with acute coronary syndrome after PCI
2019-002391-13Phase 3Completed
- Sponsor
- Policlinico Federico II
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Policlinico Federico II. Primary endpoint: Pre-dose P2Y12 reaction units at 14 days. Started Oct 2020; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2019-002391-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002391-13.